UK Prime Minister's adviser pressures AstraZeneca over $400bn merger plan
Britain’s top business envoy warned AstraZeneca’s CEO that the proposed $400 billion merger with Bristol Myers Squibb would trouble the government, contributing to the deal’s abandonment.
A proposed $400 billion combination of AstraZeneca and Bristol Myers Squibb sparked alarm at the highest levels of the UK government, prompting Varun Chandra, the prime minister’s chief business envoy, to contact AstraZeneca CEO Sir Pascal Soriot directly. The outreach followed one outlet's report that the two companies were negotiating one of the largest mergers ever. While Chandra did not explicitly order the deal to be halted, his warning added to mounting shareholder opposition, which saw AstraZeneca’s shares fall 9% in London.
Facing criticism that the merger signaled a lack of confidence in organic growth, the board chose to walk away from the talks. The incident illustrates Prime Minister Andy Burnham’s determination to retain British corporate assets, even though the government’s formal tools to block outbound investment are limited. AstraZeneca’s recent dual-listing in the United States reflects a broader trend of UK firms seeking deeper capital markets abroad.
Why it matters
It shows how government pressure can shape major cross-border deals and affect the future of UK-based pharmaceutical giants.
In this story
